1072 results about "Target therapy" patented technology

Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted thermotherapy that comprises a bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheleoid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.

The present invention concerns methods and compositions for inhibiting angiogenesis and / or tumor growth, survival and / or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and / or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.

Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.

An applicator for delivering targeted radiation brachytherapy to tissue adjacent a cavity of a patient. The applicator includes a balloon adapted for introduction to the cavity of the patient, wherein the balloon has a deflated state in which the balloon is adapted for insertion into the cavity and an inflated state in which the balloon is enlarged for at least partially filling the cavity of the patient. The balloon moves from the deflated state to the inflated state upon introduction of pressurized fluid to an interior of the balloon. The applicator also includes a conduit in fluid communication with the interior of the balloon for introducing pressurized fluid to the interior of the balloon to move the balloon from the deflated state to the inflated state, and a catheter extending over at least a portion of the balloon for delivering radiation from a radiation source to the tissue adjacent the cavity.

Disclosed are thermotherapeutic compositions for treating disease material, and methods of targeted therapy utilizing such compositions. These compositions comprise a) stable single domain magnetic particles; b) magnetic nanoparticles comprising aggregates of superparamagnetic grains; or c) magnetic nanoparticles comprising aggregates of stable single magnetic domain crystals and superparamagnetic grains. These compositions may also comprise a radio isotope, potential radioactive isotope, chemotherapeutic agent. These methods comprise the administration to a patient's body, body part, body fluid, or tissue of bioprobes (energy susceptive materials attached to a target-specific ligand), and the application of energy to the bioprobes so as to destroy, rupture, or inactivate the target in the patient. Energy forms, such as AMF, are utilized to provide the energy. The disclosed methods may be useful in the treatment of a variety of indications, including cancers, diseases of the immune system, central nervous system and vascular system, and pathogen-borne diseases.

Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and / or extent of a MN / CA9 gene expression product in a sample from the affected subject, wherein if 50% or fewer cells are found to express the MN / CA9 gene, then the subject is considered to have a poorer prognosis. MN / CA9 gene expression products useful in the prognostic methods include MN protein, MN polypeptide and / or MN nucleic acids. The methods are useful as an aid in the selection of treatment for a patient with renal cell carcinoma, alone or in combination with conventional tumor stage and / or grade information. The methods of the invention can be used, for example, to identify those patients requiring more aggressive therapy regimens, or those patients most likely to respond to adjuvant immunotherapies, particularly MN / CA IX / CA9-targeted therapies.

A method of targeting therapy such as radiation treatment to a patient includes: identifying a target lesion inside the patient using an image obtained from an imaging modality selected from the group consisting of computed axial tomography, magnetic resonance tomography, positron emission tomography, and ultrasound; identifying an anatomical feature inside the patient on a static ultrasound image; registering the image of the target lesion with the static ultrasound image; and tracking movement of the anatomical feature during respiration in real time using ultrasound so that therapy delivery to the target lesion is triggered based on (1) movement of the anatomical feature and (2) the registered images.

Provided herein are cells, vectors and viruses in association with a mutant polypeptide that has emerged in response to a therapeutic or prophylactic agent; compositions comprising such cells, vectors and viruses and methods for their use in eliciting an immune response to the mutant polypeptide. In some examples, the immune response is a cellular immune response.

The present invention provides antibody-based arrays for detecting the activation state and / or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.

Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents.

Fusion of the viral envelope, or infected cell membranes with uninfected cell membranes, is an essential step in the viral life cycle. Recent studies involving the human immunodeficiency virus type 1(HIV-1) demonstrated that synthetic peptides (designated DP-107 and DP-178) derived from potential helical regions of the transmembrane (TM) protein, gp41, were potent inhibitors of viral fusion and infection. A computerized antiviral searching technology (C.A.S.T.) that detects related structural motifs (e.g., ALLMOTI 5, 107x178x4, and PLZIP) in other viral proteins was employed to identify similar regions in the Epstein-Barr virus (EBV). Several conserved heptad repeat domains that are predicted to form coiled-coil structures with antiviral activity were identified in the EBV genome. Synthetic peptides of 16 to 39 amino acids derived from these regions were prepared and their antiviral activities assessed in a suitable in vitro screening assay. These peptides proved to be potent inhibitors of EBV fusion. Based upon their structural and functional equivalence to the known HIV-1 inhibitors DP-107 and DP-178, these peptides should provide a novel approach to the development of targeted therapies for the treatment of EBV infections.

The invention relates to a preparation method and application of an autologous CAR (chimeric antigen receptor)-T cell. An established CD28-CD137-CD19-CD3 full-length gene is guided into a T-cell of a patient by a CRISPR / Cas9 technology to prepare the CAR-T cell, and the CAR-T cell is subjected to expansion in vitro and then returns in the body of the patient to perform anti-tumor treatment. Compared with the traditional tumor treatment method, the method has the advantages that the method is cell targeted therapy and small in side effect; the gene modified T cell can stably express an antigen binding domain on the surface and identify a target antigen, and does not have MHC limit; and the tumor treatment effect is improved.

Gene expression profiling and hierarchical clustering analysis readily identify differential gene expressions in normal renal epithelial cells and renal cell carcinomas. Genes identified by this analysis would be useful for diagnosis, prognosis and development of targeted therapy for the prevention and treatment of conventional renal cell carcinoma.

A biomedical device assembly, such as a stent, for the targeted treatment of a tissue, such as the inhibition of restentosis. The stent is coated with an antigen, which is an example of a lock. The antigen can be bound by a labelled antibody, which is an example of a key and an effector. The antibody is preferably labelled with a radioactive source. According to one method of preparing the biomedical device assembly, after the stent has been placed in the blood vessel of the subject, the antibody is injected. The antibody then binds to the antigen on the stent, thereby localizing the radioactive source to the area to be treated, for example for restenosis. Other biomedical devices, such as a coil, an artificial valve or a vascular graft, could also be used in the place of the stent. The biomedical device could be placed in another biological passageway, such as the gastrointestinal tract, an airway or the genitourinary tract.

The invention relates to a preparation method of a protein magnetic imprinting nano sphere, in particular to a preparation method of a protein magnetic imprinting nano sphere which takes one of hemoglobin, muramidase or serum protein as template molecules; the preparation method includes the following steps: synthesizing magnetic nano particles which are Fe3O4 nano particles covered with silicon dioxide on the surfaces; carrying out silanization to the amino-groups on the surface of the magnetic sphere; using glutaric dialdehyde to connect protein; using silylation agent to fix the space structure of template protein; alkaline eluting the protein on the surface of the magnetic sphere to form imprinting sites. The hemoglobin, muramidase or serum protein magnetic nano imprinting polymer sphere prepared by the invention combines the precise and specific identification property of molecular imprinting and the quick separation property of the magnetic nano sphere under the action of an external magnetic field, integrates the advantages of molecular imprinting and the magnetic nano sphere, avoids complex centrifugation operation, plays vital roles in the separation of cells, protein and nucleic acid, the detection of biomolecules, tumor diagnosis and medicine targeting therapy and has promising application prospect in the field of isolation analysis.

The present invention relates generally to targeted therapy with RNA interference, more specifically, to energy susceptible nanoscale material compositions, devices for use with magnetic material compositions, and methods related thereto for targeted therapy via targeted delivery of energy susceptible nanoscale magnetic particles carrying short interfering RNA constructs.

The invention belongs to the field of gene engineering, and relates to chimeric antigen receptor of anti-human CD19 antigen and application thereof. The chimeric antigen receptor of anti-human CD19 antigen comprises polypeptide (scFv) for recognizing human CD19 antigen, a hinge region, a transmembrane region and an intracellular signal domain which are connected in sequence, wherein an amino acid sequence of the polypeptide (scFv) for recognizing human CD19 antigen is as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4. The chimeric antigen receptor can be more stably expressed in T lymphocyte, has the capacity for properly removing cancer cell, can not only maintain the positive rate of CD19 targeted chimeric antigen receptor during the cell culture of a patient, but also enhance the capacity for CAR-T multiplication and tumor killing, does not have toxic and / or side effects on antigen-negative cell, and can be applied to the targeted therapy of tumor.

The invention discloses a humanized monoclonal antibody targeting to human CD19 antigen. The humanized monoclonal antibody is applied to construction and preparation of chimeric antigen receptor T cells; and subsequent in-vitro experiments verify the tumor treatment effect of the chimeric antigen receptor T cells. A chimeric antigen receptor targeting to the human CD19 antigen is composed of a leader peptide, a single-chain antibody targeting to the human CD19 antigen, a hinge area for connection with ScFv, a transmembrane domain and an immune receptor tyrosine activation motif; a lentiviral expression vector is constructed from the chimeric antigen receptor and then used for infection of immune cells, so the chimeric antigen receptor targeting to the human CD19 antigen can be expressed in the immune cells; and tumors expressing the CD19 antigen are killed by recognizing the CD19 antigen on the surfaces of tumor cells, so the purpose of tumor treatment is achieved. The invention provides a novel tool for targeting therapy of tumors.

Devices, systems and methods for reducing migration of leads, catheters and similar devices are provided. In particular, devices, systems and methods are provided for creating a slack anchor which assists in maintaining the lead or catheter in a desired position. In some embodiments, the slack anchor is created within the epidural space. When targeting nerve anatomy within the spinal column or in the vicinity of the epidural space, anchoring within the epidural space allows the associated lead or catheter to be anchored as close to the target therapy site as desired or possible. By anchoring close to the target therapy site, the risk of movement or migration is significantly reduced or eliminated.

The invention relates to a bio-assay reagent for early diagnosis of tumor and a prodrug for the targeted therapy of tumor, in particular to a targeted tracing noble metal fluorescence probe and an anti-tumor prodrug. Through experiment, the synthesized probe does not have cytotoxicity and is safe and effective, can realize the level imaging of cells and the imaging of in-vivo tumor, and has good prospect when used as the targeted fluorescence probe or the prodrug.

Devices, systems and methods for reducing migration of leads, catheters and similar devices are provided. In particular, devices, systems and methods are provided for creating a slack anchor which assists in maintaining the lead or catheter in a desired position. In some embodiments, the slack anchor is created within the epidural space. When targeting nerve anatomy within the spinal column or in the vicinity of the epidural space, anchoring within the epidural space allows the associated lead or catheter to be anchored as close to the target therapy site as desired or possible. By anchoring close to the target therapy site, the risk of movement or migration is significantly reduced or eliminated.

The present invention relates to a superparamagnetic composite microparticle medicine-carrying body which can be mainly used for making magnetic target therapy and its preparation method. The invented magnetic composite microparticle medicine-carrying body is composed of magnetic composite microparticle and medicine-carrying layer which can be used for covering exterior of said magnetic composite microparticle. Said invention is characterized by that it utilizes the property of high surface activity of gold shell layer or colloidal gold of superparamagnetic composite microparticle to directly cover medicine or firstly utilizes the property of high surface activity of the gold shell layer or colloidal gold of superparamagnetic composite microparticle to make its surface be covered with high-molecular material, then utilizes the affinity adsorption or covalent linkage of high-molecular material to medicine to cover the medicine, also can make the surface of superparamagnetic composite microparticle be covered with the high-molecular material and medicine cross-linked or target preparation and medicine cross-linked or high-molecular material, target preparation and medicine cross-linked composite body layer.

Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and / or in vivo non-invasive imaging and / or assessments.

The present invention provides for the identification of autoreactive T cell populations from individuals having autoimmune diseases, such as multiple sclerosis and EAE. Peptoids recognized by autoreactive T cells can be used to identify various types of autoimmune disease, and can also be used to target therapies against such populations.

The invention belongs to the field of genetic engineering, and concretely relates to a BCMA-targeting chimeric antigen receptor and an application thereof. The chimeric antigen receptor comprises an antigen recognition region, a hinge region, a transmembrane region and an intracellular signal domain; and the amino acid sequence of an extracellular recognition region is represented by SEQ ID NO.1 or SEQ ID NO.2 or SEQ ID NO.3. The chimeric antigen receptor can effectively remove BCMA-expressing tumor target cells after being expressed in immune cells, has no toxic or side effects on antigen-negative cells, and can be used for the targeted therapy of tumors.

The invention relates to a tumor targeted polypeptide, and a preparation method and application thereof. The polypeptide is disclosed as the following general formula: X1X2X3X4X5WX6X7. The invention also relates to a nucleotide sequence for coding the polypeptide, an expression vector for expressing the polypeptide and a host cell. The invention also relates to a bivalent, multivalent or polypeptide coupling substance formed by the polypeptide, a pharmaceutical composition formed by the polypeptide used as a targeted polypeptide and a preparation / development preparation capable of killing cancer cells, and application thereof. The polypeptide is the most ideal tumor targeted polypeptide at present, has important application value in tumor molecular diagnosis and targeted therapy, provides important theoretical and practical basis for early diagnosis, targeted therapy and the like of mammary cancers, lung cancers and many other tumors, and thus, has wide application prospects.

The invention relates to a group of anti-human CD146 molecules which are developed by utilizing the biological technology and an established high-sensitive sandwich ELISA method for detecting the solubility CD146. The invention includes anti-human CD146 mouse monoclonal antibodies of AA1, AA2, AA3, AA4, AA5 and AA7, and the method of utilizing the combination of the antibodies and the sandwich ELISA specificity for detecting the solubility CD146. The group of antibodies can identify the human source CD146 on the molecular, the cellular and the tissue levels, which can be divided into two categories based on the identified different epitopes. The sandwich ELISA method which is combined by the antibody AA1 and another strain of anti-human CD146 mouse monoclonal antibody AA98 can detect the solubility CD146 at each milliliter nano-gram level. The antibodies and the detection means can become the effective detection or diagnosis tools and method in the basic research or the clinical application and provide good carriers for the targeted therapy of the CD146-related diseases at the same time.

The invention discloses glycosylated boron dipyrromethene fluorophore derivatives as well as a preparation method and application of the glycosylated boron dipyrromethene fluorophore derivatives. The method comprises the following steps: by taking glucose and glucosides thereof as action targets, connecting covalent bonds of the action targets to boron dipyrromethene fluorophore derivatives for photodynamics therapy, so that a third generation photosensitizer against cancer which can be used for targeted therapy is obtained. The dipyrromethene fluorophore derivatives containing glucose and glucosides are taken as study researches, activity study of in-vitro breast cancer-resistant cells MBA-MD-231 is expanded, a prodrug suitable for molecular targeted therapy is screened, and a foundation is laid for applying the glycosylated boron dipyrromethene fluorophore derivatives to targeted therapy of cancers. Moreover, the compound synthesis method is simple, readily available in raw materials, low in cost, few in side reactions, high in yield and simple in purification, and industrial production is promoted.